Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KLK7 | P49862 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | F12 | P00748 | 3/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12882199 | 0.79 | HSD17B10 (0.46) | KMT2AHSD17B10NPC1RAB9AKDM4E | |
| SCHEMBL16757104 | 0.75 | HPGD (0.40) | KMT2ANPC1RAB9AF12F2 | |
| SCHEMBL7635955 | 0.74 | PLAU (0.45) | KMT2ANPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL27684258 | 0.73 | NPC1 (0.48) | KMT2AHSD17B10NPC1RAB9AKDM4E | |
| SCHEMBL27819780 | 0.71 | PARP1 (0.43) | MAPTTHRB | |
| SCHEMBL16756835 | 0.70 | TSHR (0.45) | KMT2AMAPK1MAPTF12TSHR | |
| Methane SCHEMBL27916787 | 0.69 | NOTUM (0.42) | HSD17B10MAPK1MAPTCYP1A2CYP2C19 | |
| SCHEMBL335681 | 0.68 | MAPK1 (0.77) | MAPK1MAPTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL29415167 | 0.68 | MAPK1 (0.77) | MAPK1MAPTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL27740855 | 0.67 | NOTUM (0.41) | HSD17B10MAPK1MAPTCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595390-B2 | Industrially scalable nucleoside synthesis | NOVARTIS AG (CH) | 2009-09-29 | — | — | US | disclosed |
| EP-1620451-A4 | INDUSTRIALLY SCALABLE NUCLEOSIDE SYNTHESIS | NOVARTIS AG (CH) | 2009-02-18 | — | — | EP | disclosed |
| EP-1620451-A2 | INDUSTRIALLY SCALABLE NUCLEOSIDE SYNTHESIS | Idenix (Cayman) Limited (KY) | 2006-02-01 | — | — | EP | disclosed |
| US-20050004357-A1 | Industrially scalable nucleoside synthesis | NOVARTIS AG (CH) | 2005-01-06 | — | — | US | disclosed |
| WO-2004096149-A2 | INDUSTRIALLY SCALABLE NUCLEOSIDE SYNTHESIS | IDENIX (CAYMAN) LIMITED (KY) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004357-A1 | Industrially scalable nucleoside synthesis | ADA, DCTD, PNP | KMT2A 3613/4885HSD17B10 2134/4885NPC1 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.